30th May 2026

Long-Term Management of STEMI

Medications

• Aspirin: Continue lifelong, with a P2Y12 inhibitor for up to 12 months as part of dual antiplatelet therapy.
• ACE inhibitor: For patients with reduced ejection fraction or heart failure.
• Beta-blocker: To reduce the risk of reinfarction and improve survival.
• Statin: To manage cholesterol and reduce cardiovascular risk.

Cardiac Rehabilitation and Risk Factor Modification

• Enrol in cardiac rehabilitation to improve recovery and reduce the risk of future events.
• Address modifiable risk factors for cardiovascular disease, including:
• Smoking cessation
• Blood pressure control
• Diabetes management
• Dietary changes and exercise
• Weight management

These measures are crucial for improving long-term outcomes, preventing reinfarction, and reducing the risk of complications.

Prevention and Follow-up

• Primary Prevention: Encourage lifestyle changes and medications (statins) for high-risk individuals.
• Secondary Prevention: Lifestyle modifications, cardiac rehabilitation, medications (dual antiplatelet therapy, beta-blockers, statins, ACE inhibitors).
• Follow-up: Survivors should be evaluated within 2-3 weeks post-discharge. Continue optimal medical therapy and assess ejection fraction.

Complications

• Short-term: Sinus bradycardia, heart block, recurrent chest pain, acute mitral regurgitation, ventricular septal defects, and pericarditis.
• Long-term: Congestive heart failure, recurrent ischemia, depression, ventricular arrhythmias.

Prognosis

The prognosis is better with early reperfusion, adherence to therapy, and risk factor modification. In-hospital mortality is around 9%, and elevated troponin levels indicate a worse prognosis. Major bleeding events increase 1-year mortality risk. Evidence-based treatments improve patient outcomes.